RecruitingPhase 1Drug trial
TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B
The goal of this clinical trial is to learn if HEPLISAV-B, a vaccine that is approved to prevent hepatitis B infection in people that are not already infected, is safe in people already chronically infected with hepatitis B. The main quiestions it aims to answer are:
1. Is HEPLISAV-B safe in people with chronic hepatitis B?
2. What side effects, if any, could HEPLISAV-B cause in people with chronic hepatitis B?
3. How does HEPLISAV-B affect the cells that fight chronic hepatitis B?
Participants will:
* Receive HEPLISAV-B as an injection in the muscle, one injection every 4 weeks, for a total of 2 injections.
* Visit the clinic a total of 5 times, and have 3 phone follow ups over 14 months.
* Be asked if they are having any side effects from HEPLISAV-B.
* Have blood samples collected.